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Shock due to severe plasma leakage may happen in infectious diseases such as severe dengue and sepsis due to various bacterial
infections, which may be deleterious and may lead to death. Various substances and proteins are knownto modulate the eﬀects of
proleakage mediators and counteract the deleterious eﬀect of plasma leakage. Someof the various substances and proteins such as
focal adhesion kinase (FAK), the Rho GTPases, protein kinase A, and caveolin-1 have dual actions; therefore they are not suitable
for therapy. However, sphingosine1phosphate and its receptor agonists,Angiopoetin-1, Slit, and Bbeta15–42 may be promising.
1.Introduction
Shockduetosevereplasma leakagemay happenininfectious
diseases such as severe dengue [1], and sepsis due to various
bacterial infections [2], which may be deleterious and may
lead to death. Plasma leakage is caused by a substantial
increase in endothelial permeability that is mainly due to
loosening of interendothelial junction and focal adhesion
due to host’s response to infectious pathogens. Loosen-
ing of interendothelial junction is triggered by proleakage
mediators such as thrombin, bradykinin, histamine, reactive
oxygen species (ROS), vascular endothelial growth factor
(VEGF), tumor necrosis factor alfa (TNFα), and bacterial
lipopolysaccharides (LPS) that are alternatively called as
endotoxin [3]. Currently, proteins that are involved in the
interendothelial tightening or loosening events are accumu-
lating. Therefore, this review will address interendothelial
junction,focaladhesion,andvarioussubstancesandproteins
that may modulate the eﬀects of proleakage mediators to
counteract the deleterious eﬀect of plasma leakage. Finally,
future clinical application will be discussed.
2.InterendothelialJunctionand
Focal Adhesion
Inter-endothelial junctions (IEJs) responsible for the occur-
rence of plasma leakage are tight junctions (TJs) and
adhering junctions (AJs) that form intercellular zipper-like
structures between two cell borders. Tight junctions are
composed of claudins, occludins, and junctional adhesion
molecules (JAMs), that are connected to actin cytoskeleton
by zonula occludens protein (ZO-1), while AJ are composed
of calcium ion-dependent vascular endothelial- (VE-) cad-
herin that are linked to cytoskeletal actin through catenins,
namely, α, β, γ, and p120-catenins [3]( Figure 1).
In addition, endothelial cell membrane contains integrin
that is a transmembrane protein, which forms focal adhe-
sion to subendothelial extracellular matrix (ECM) proteins
that consist of collagen IV, ﬁbronectin, laminin, entactin,
chondroitin sulfate, heparan sulfate, perlecan, syndecan,
thrombospondin and secreted protein acidic and rich in
cysteine (SPARC). Subendothelial ECM forms a highly
elastic basement membrane with great tensile strength [3]
(Figure 1).
Further, integrin also directly or indirectly binds other
focal adhesion associated proteins, that is, talin, vinculin, α
actinin, paxillin, ﬁlamin, zyxin, and tensin [3, 4], and via
these proteins are connected to cytoskeletal actin (Figure 1).
These focal adhesion proteins interact with IEJ proteins.
Therefore, TJs, AJs, and focal adhesions provide adhesive
strength between adjoining cells that provide barrier func-
tions [3].
When the IEJs are established, platelet endothelial cell
adhesion molecule-1 (PECAM-1) rapidly occupies these2 ISRN Pharmacology
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Figure 1: Interendothelial junctions and focal adhesions Oc = occludin, Cl = claudin, JAM = junctional adhesion molecules, Zho = zonula
occludens proteins (zho-1), VE cadherin = vascular endothelial cadherin, β = β catenin, γ = γ catenin, p120 = p120 catenin, Arp = Arp2/3,
WASP = Wiskott-Aldrich syndrome protein, Cdc = Cdc42, Vin = vinculin, Px = paxillin, αIn = α integrin, βIn = β integrin, FAK = focal
adhesion kinase,Cav = caveolin-1, Fil = ﬁlamin,Ten = tensin, – ·–·–·– = actin. Oc, Cl, JAM, and Zho are part of tight junctions, while VE
cadherin, α, β, γ, p120 catenin are part of adhering junctions that can be modulated by Arp, WASP, and Cdc.
junctions, and prevents the expression of leukocyte adhesion
m o l e c u l e ss u c ha sE - s e l e c t i n ,a n dt h u sp r e v e n t sl e u k o c y t e
transmigration through the IEJs [5].
Proleakage mediators may interact with TJ, AJ, or ECM
proteins and stimulate the pathway that cause loosening of
IEJ, and ends up in plasma leakage. However, restoration
of barrier function will usually follow due to substances
and proteins that counteract the proleakage mediators and
therefore are involved in the tightening and restoring of the
IEJ [3].
3.Substances andProteins to Counteract
ProleakageMediators
Various substances and proteins may counteract proleakage
mediators and restore barrier functions; they are focal
adhesion kinase (FAK), caveolin-1, Cdc42 and Rac, cAMP,
protein kinase A (PKA) and adenylate cyclase, sphingosine
1phosphate (S1P) and its receptor agonist, angiopoetin-1
(Ang-1), Slit, and Bbeta15–42.
3.1. Focal Adhesion Kinase and Its Associated Proteins. Focal
adhesion kinase is a protein with tyrosine kinase activity
that regulates actin dynamics, binds to integrins, and is
responsible for focal adhesi o nt oE C M .I na d d i t i o n ,F A K
binds a triple enzyme called Trio that interacts with RhoA
and Racand is responsiblefor theinhibitionofRhoAactivity
at focal adhesions, which protect against barrier disruption
[3, 6, 7].
RhoA is one of the Rho-family small GTPases (Rho
GTPases), which has dual action, that is, at basal expression
level, it plays a role in intrinsic barrier protection at cell
margins, but thrombin-induced increased activity of RhoA
causes barrier disruption at focal adhesions [8].
Thrombin-activated RhoA plays a role in actin stress
ﬁber formation; and contraction of the stress ﬁbers may
disrupt the focal adhesion, and thus disrupt barrier function
[8]. However, RhoA activation due to nonfunctioning FAK
is inhibited by C3 toxin. Therefore, C3 toxin may restore
endothelial barrier function due to nonfunctioning FAK
[3]. Studies showed that FAK induced inhibition of RhoA
activity needed cooperation of FAK-associated proteins,
that is, GTPase regulator associated with FAK (GRAF) and
190Rho GTPase activating protein (190RhoGAP) [3, 9, 10]
(Figure 2).
Overall, FAK and its associated proteins (GRAF and
190RhoGAP) together with Trio and C3 toxin are supposed
to restore increased vascular permeability due to proleakage
mediators such as thrombin, histamine, and VEGF by
recruiting focal adhesions [3, 11]. However, FAK is also
required for thrombin-induced cell contraction that ends up
in barrier disruption [12, 13].ISRN Pharmacology 3
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Figure 2: The role of focal adhesion kinase, its associated proteins,
Rho GTPases, cAMP, angiopoetin-1, and Bbeta15–42 peptide
in barrier maintenance. FX06 = Bbeta15–42 peptide, Ang-1 =
angiopoetin-1, Prolea = proleakage mediators, Rho = Rho A,
FAK = focal adhesion kinase, Gra = GTPase regulator associated
with FAK (GRAF), RhoG = 190Rho GTPase activating protein
(190RhoGAP), C3 = C3 toxin, N = normal level, Incr = increased
level, Rp = Rap-1, PKA = protein kinase A, VASP = vasodilator
stimulated phosphoprotein, Barrier str = barrier strengthening,
Barrier disr = barrier disruption, solid line = contributing factor,
and dashed line = inhibiting factor. Various substances are involved
inbarrier strengthening/disruption.Somesubstances havediﬀerent
eﬀects that depend on the presence or the absence of proleakage
mediators (normal condition); for instance, Rho contribute to
barrier strengthening in normal condition, but contribute to stress
ﬁber formation in the presence of proleakage mediators.
3.2. Caveolin-1. Caveolin-1 is one of the caveolae mem-
brane-associated regulatory proteins. Moreover, caveolin-1
has important function in signal transduction as well as
molecular transport such as endocytosis and transcytosis
across endothelium [14]. Integrin-caveolin-1 interaction
is supposed to support endothelial barrier function [3].
Caveolin-1 binds integrin (Figure 1)[ 3, 15], and caveolin-
1 expression inhibition causes an increase in endothelial
paracellular permeability [16] due to suppression of integrin
signalinganddecreaseinfocaladhesionformation[3].How-
ever,caveolin-1regulatesVEGF-inducedVEGFR2autophos-
phorylation that is followed by downstream signaling [14],
which may trigger plasma leakage. Regulation of VEGF-
inducedVEGFR2autophosphorylationissupposedtobedue
to compartmentalization of certain signaling molecules[14].
3.3. Cdc42 and Rac. Cdc42 and Rac are another Rho
GTPases. Studiesshowed that in endothelial cells, Cdc42and
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Figure 3: The role of Rho GTPases and sphingosine 1phosphate
in barrier maintenance. Prolea = proleakage mediators, VEGF =
VEGF-165 (the predominant isoform of VEGF A), GIT 1 = G
protein-coupled receptor kinase interactor-1, Pix = p21-activated
kinase-interacting exchange factor, FAK = focal adhesion kinase,
SFK = Src family kinase, S1P = sphingosine 1phosphate, S1PR =
sphingosine 1phosphate receptor, Cdc = Cdc42, Rho = RhoA,
α = α catenin, β = β catenin, Sc = Scar, WASP = Wiskott-
Aldrich syndrome protein, Arp = Arp2/3, PAK = p21-activated
kinase, MCLK = myosin light chain kinase, Barrier str = barrier
strengthening, Barrier disr = barrier disruption, solid line =
contributing factor, anddashed line = inhibitingfactor.The various
Rho GTPases and S1P have dual role in barrier maintenance.
Rac regulated the formation of membrane ruﬄe associated
actin ﬁlaments [17], which may induce the formation of
IEJs, especially formation of AJ [3]. Moreover, Cdc42 and
rac function is regulated by FAK [18]t h a tc a u s e sa c t i np o -
lymerization [19], and AJ assembly [20]. Regulation by FAK
involves other proteins, that is, G protein-coupled recep-
tor kinase interactor-1 (GIT-1) and p21-activated kinase-
interacting exchange factor (PIX) [3, 21].
In addition, Cdc42 and Rac regulate actin-myosin inter-
action through p21-activated kinase (PAK) that inhibits
myosin light chain kinase (MLCK) activity [22]. However,
PAK has dual action, as constitutively active PAK can phos-
phorylate myosin light chain (MLC) and causes endothelial
contraction, and thus barrier disruption [22, 23].
Another possible targets of Cdc42 are Wiskott-Aldrich
syndrome protein (WASP), WASP family verprolin-homol-
ogous (WAVE) that is alternatively called Scar), and Arp2/3
that are activators of actin polymerization, which might
facilitate AJ formation [24, 25]( Figure 3).
Thrombin induced plasma leakage due to AJdisassembly
is usually transient, and is followed by Cdc42 delayed4 ISRN Pharmacology
activation that will restore the barrier function due to AJ
reassembly [3, 20].
However, Cdc42 and rac have dual actions. Besides
facilitating the formation of IEJs, cdc42 may increase vas-
cular permeability by loosening AJ due to loosening α-β
catenin interaction [3, 20]( Figure 3). Rac is required to
maintain barrier integrity, as proleakage mediators such as
thrombin decreases Rac activity and causes imbalance in
the proportion of activated rac versus RhoA that ends up
in plasma leakage. However, another proleakage mediator,
namely, VEGF-165 (the predominant isoform of VEGF A)
causes Src family kinase (SFK) dependent activation of Rac-
1 that ends up in increased permeability [26, 27].
3.4. cAMP, PKA, and Adenylate Cyclase. In endothelial cells,
cAMP is synthesized by adenylate cyclase and controlled
by phosphodiesterase. On endothelial barrier, cAMP shows
dual action, that is, barrier disruption and barrier protective
action [3]. Increase in cytosolic cAMP level due to Pseu-
domonas aeruginosa EcoY disrupts the endothelial barrier
[28], while in the presence of permeability increasing medi-
ators, cAMP may strengthen endothelial barrier through 2
mechanisms, that is, thePKA dependentand PKAindepend-
ent mechanisms [3].
In the PKA-dependent mechanism cAMP activates PKA
that prevents RhoA activation [29], and thus inhibits
endothelial contraction [3]. In addition, PKA phosphory-
lates vasodilator stimulated phosphoprotein (VASP), which
causes occludin, JAM, and ZO-1 binding and promotes
stabilization of IEJ [3]. In the PKA independent mechanism,
cAMPincreases Rap1(amemberoftheRasfamily)[30]that
inducesphosphorylation ofRho A [31], followed by decreas-
ing RhoA activity, thus strengthen the IEJs [3]( Figure 2).
3.5. S1P and S1P Receptor Agonist. Sphingosine 1phosphate
is synthesized by sphingosine kinase and degraded by either
sphingosine phosphatase or sphingosine lyase, and the three
enzymes regulate S1P plasma level [32]. Platelets are the
primary storage of S1P, as platelets lack the degrading
enzymes. Endothelial cells have S1P receptors and might be
continuously exposed to platelet released S1P that is bound
to albumin, at a normal serum level of 250 to 500nM [3].
The eﬀect of normal level of S1P on endothelium is
to maintain the IEJs. Further, in thrombin-induced barrier
dysfunction, S1P accelerate the recovery of barrier function
in vitro [33, 34]. However, at high concentration (5μM) S1P
activates RhoA and stress ﬁber formation, thus disrupt the
IEJs [35].
The mechanism for the maintenance of IEJs by phys-
iological level of S1P requires binding to S1P receptors,
which are G protein-coupled receptors and are members of
the previously called endothelial diﬀerentiation gene (edg)
family of receptors, namely, edg-1or S1P1 and edg-3 or S1P3
receptors [33, 36]. Further, it involves rac, as well as Rho
kinase-dependent PAK activation that plays a role in cortical
actin assembly due to phosphorylation of coﬁlin, which is
an actin ﬁlament regulatory protein (Figure 3). In addition,
tyrosine kinase activation is involved in cortical cytoskeletal
rearrangement [33], followed by assembly of AJ [3, 33], and
focal adhesioncomplex(FAC)[35–37],which strengthen the
IEJs [3].
FTY720-P is a sphingosine kinase-mediated phospho-
rylation product of the potent immunosuppressive agent
FTY720. FTY720-P is regarded as agonist of S1P receptor,
as it has a high aﬃnity for G protein-coupled S1P receptor.
Uponbindingtothereceptoronendothelialcells,itmediates
Akt phosphorylation followed by AJ assembly. In vitro,
FTY720-PwasshowntocounteractVEGF-inducedincreased
permeability, and in vivo, FTY720 administration strongly
blocked VEGF-induced plasma leakage [36].
3.6. Angiopoetin-1. Angiopoetin-1 and VEGF are important
regulators of embryonic and postnatal neovascularization.
In later stages of embryonic angiogenesis Ang-1 cooperate
with VEGF in inducing the formation of mature endothelial
barrier [3]. Further, Ang-1 opposes proleakage-mediator-
induced, such as VEGF-induced [38], as well as thrombin-
[3], platelet activating factor (PAF)-, bradykinin- and hista-
mine-induced [39] endothelial permeability increase.
The mechanisms of Ang-1-induced permeability inhi-
bition are supposed via the inhibition of RhoA pathway
(Figure 2)[ 3]. Ang-1maintain the localization of PECAM-
1 into IEJs, and counteract proleakage-mediator-induced
phosphorylation of PECAM-1 and VE-cadherin and also
restore the impaired association between catenins and VE-
cadherins, and therefore repair the impaired barrier integrity
due to proleakage mediators [5]( Figure 4).
Moreover, Ang-1 suppresses VEGF-induced upregula-
tion of intercellular adhesion molecule-1 (ICAM-1), vas-
cular cell adhesion molecule-1 (VCAM-1), and E-selectin
expression, followed by suppression of leukocyteadhesion to
endothelialcellsandtransmigration throughIEJs, andﬁnally
counteract VEGF induced plasma leakage by maintaining
barrier integrity. Ang-1 suppression of those adhesion
molecules is supposed to be mediated by binding to its
receptor, namely, Tie2 receptor that strongly activates the
phosphatidylinositol 3 -kinase/Akt pathway [40]( Figure 4).
The pathway suppress nuclear factor kappa B (NF-κB) that
is activated upon VEGF binding to its receptor, namely, the
VEGF receptor2 (VEGFR2), that is alternatively called as
fetal liver kinase-1(Flk-1)/kinase insert domain containing
receptor (KDR) [40].
3.7. Slit. Slit is the soluble ligand of the Roundabout (Robo)
receptor that was initially found in axons, but later, an
endothelial speciﬁc Robo that is called Robo4 was found.
In axons, Slit-Robo is part of a signaling pathway that is
involved in axon guidance, while in endothelial cells, Slit-
Robo maintains vascular barrier in the mature vascular
network, by inhibiting endothelial hyperpermeability that is
induced by proleakage mediators [41].
The mechanism of barrier maintenance involves inter-
action of Slit-Robo4 with a family of intracellular adaptor
proteins,namely,paxillinandHic-5.Thisinteractionrecruits
GIT1 that is one of the Arf-GAPs and causes inactivationISRN Pharmacology 5
of Arf (a small GTPase) followed by inhibition of Rac
activation, which leads to inhibition of plasma leakage [41].
In VEGF-165-induced plasma leakage, slit2-Robo4 in-
hibitRac-1activationduetoinhibitionofSFK-Racsignaling,
namely, phosphorylation of SFKs, including Fyn, Yes, and
Src, which occurred downstream of the VEGFR2 that is
autophosphorylated upon binding to VEGF-165 [42]. In
addition, Slit-Robo4 inhibits VEGF-165 induced plasma
leakage by blocking the activation of Arf6 [41].
The IEJ components that are involved in slit-Robo4 in-
hibition of plasma leakage are VE-caherin and p120 catenin
at AJs. Slit-Robo4preventsdissociation ofVE-cadherin from
p120 catenin, which happens in plasma leakage, and there-
fore prevents AJ disruption (Figure 4) by preventing dis-
placement of VE-cadherin to the interior of the cell [2, 43].
3.8. Bbeta15–42. Bbeta15–42 (alternatively called as FX06)
is a ﬁbrin-derived natural peptide that occurred after ﬁbrin
degradation by plasmin. The peptide is recently regarded
as a signaling molecule that signiﬁcantly reduces plasma
leakage in animal models, as it stabilizes endothelial barriers
[13].
The mechanism involves activation of Rac and preven-
tion of RhoA activation. Further, the peptide restores the
imbalanceinactivatedRac-RhoAandcounteractsthrombin-
induced stress ﬁber formation and myosin light chain
phosphorylation, thus preventing cell contraction and the
loosening of IEJs. Prevention of RhoA activation is mediated
through Fyn that dissociates from VE-cadherin at AJs,
upon exposure to the peptide. Subsequently, Fyn associates
with p190RhoGAP and prevents RhoA activation (Figure 2).
Moreover, prevention of cell contraction also involves FAK,
as the peptide causes diﬀuse distribution of FAK in the
cytosol, instead of localization of FAK at the tip of stress
ﬁbers that happens in the presence of thrombin alone
[13].
4.FutureClinicalApplication
As some of the various substances and proteins such as FAK,
thethreeRhoGTPases (RhoA,Cdc42,andRac),cAMP,PKA,
and caveolin-1 may have dual actions, they are not suitable
for the therapy of plasma leakage. On the other hand, S1P
and its receptor agonists, Ang-1, Slit, and Bbeta15–42 may
be promising to be studied further.
Various diseases may involved plasma leakage in various
degrees and may beneﬁt from the substances that can
prevent the occurrence or control the occurring plasma
leakage. Plasma leakage may happen in various conditions,
such as respiratory distress syndrome due to sepsis from
various etiologies, shock that is followed by multiorgan
failure due to cytokine storm as that happens in various
acute infections, conditions with tissue edema, and chronic
peripheral vascular disorders associated with diabetes [36].
Therefore, those substances need to be evaluated, ﬁrst in
animal models for those various conditions, followed by
clinical trials to conﬁrm their use in human, if studies in
animal models show promising results.
PECAM VE cad Cats
Slit Robo
Pro Lea
AM incr NFkB
Barrier disr
Akt
Tie Ang-1
P
Figure 4: The role ofangiopoetin-1 and slit in barrier maintenance
Ang-1 = angiopoetin-1, Tie = Tie2 receptor, Prolea = proleakage
mediators, P = phosphorylation, Akt = phosphatidylinositol 3 -
kinase/Akt pathway, Robo = Roundabout receptor, NFκB = nuclear
factor kappa B, AM incr = adhesion molecule increase, PECAM =
PECAM-1, VEcad = VE-cadherin, Cats = catenins, Barrier disr =
barrier disruption, solid line = contributing factor, and dashed
line = inhibiting factor.
4.1. S1P and Its Receptor Agonists. An animal study in
mice showed that S1P lacking mutant mice beneﬁted from
pretreatment with S1P1 receptor agonist (AUY954) or wild-
type erythrocytes, which restored plasma S1P levels, before
induction of plasma leakage. However, wild-type mice did
notbeneﬁtpretreatment with theS1P1receptoragonist[44].
Another study that used extravasation of FITC-dextran as
a measure of plasma leakage showed that administration of
S1Preceptoragonist(FTY720)orallybeforeinducingplasma
leakageby VEGF, potentlyreducedplasma leakagecompared
to controls [36].
However, in the animal studies S1P and its receptor ago-
nist were administered before induction of plasma leakage,
thus preventing the occurrence of plasma leakage. Whether
they can control occurring plasma leakage by restoring the
endothelial barrier remains to be established.
4.2. Ang-1. An animal study in mice showed that Ang-
1 delivery through adenoviral transduction of Ang-1 gene
followed by proleakage mediator challenge caused plasma
leakage reduction from the venules due to decrease in the
number and size of endothelial gaps [45]. Further, in a study
on patients with septic shock, Ang-1 level was signiﬁcantly
lower compared to patients with sepsis without shock [46],
and in another study, Ang-1 level in patients with sepsis
was lower compared to healthy controls [47]. These results
suggest that Ang-1 administration may be beneﬁcial to
control plasma leakage in sepsis, especially septic shock.6 ISRN Pharmacology
However, whether Ang-1 really can be used to treat
plasma leakage and not only prevents it from occurring as
was shown in the animal study remains to be established.
4.3. Slit. A study on 3 kinds of animal models, that is, for
gram-negative bacterial pneumonia, intraabdominal sepsis,
and H5N1 inﬂuenza virus infection showed that intravenous
Slit administration before the induction of disease strongly
reduced plasma leakage in the lung and other organs, and
decreased mortality in the animals, without any eﬀect on
the pathogen-induced cytokine storm [43]. As in the case
of S1P and Ang-1, Slit was administered before induction
of the various diseases, therefore, studies on already infected
animals need to be conducted to reveal whether Slit only
prevents, or is able to treat plasma leakage. The implication
if it only prevents, it should be administered early in
individuals at risk for severe disease, before plasma leakage
is prominent.
4.4. Bbeta15–42 (FX06). In an animal model for LPS pneu-
monitis with plasma leakage, FX06 treatment directly and 60
minutes afterLPS intranasal instillation signiﬁcantly reduced
plasma leakage and inﬂammation. In another animal model
for dengue shock syndrome, day 3 after infection adminis-
tration ofFX06signiﬁcantly reducedplasma leakagethrough
capillaries in the lungs and intestines, reduces hemoconcen-
tration and ﬁbrinogen consumption, and improved survival,
but did not aﬀect viral loads in serum, liver, and brain [13].
FX06 has entered phase I clinical trial that involved
30 male healthy volunteers in a randomized double blind
placebo controlled, parallel group study to test the phar-
macokinetics and safety of single ascending doses, and was
provensafe [48].Further, FX06wasused inaphase IIclinical
trial for patients with acute myocardial infarction with good
results [49]. Whether FX06 has clinical beneﬁt in plasma
leakage due to various pathogens remains to be established.
5.Conclusion
S1P and its receptor agonists, Ang-1, Slit, and Bbeta15–
42 showed promising results in preventing plasma leakage
in animal studies. Their potentials to prevent and control
occurring plasma leakage due to various diseases in human
remain to be established.
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